Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Dermatomyositis - Overview

Dermatomyositis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Dermatomyositis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Dermatomyositis - Companies Involved in Therapeutics Development

Biocon Ltd

Bristol-Myers Squibb Co

Chugai Pharmaceutical Co Ltd

Corbus Pharmaceuticals Inc

CSL Ltd

Eli Lilly and Co

GNI Group Ltd

Hope Pharmaceuticals Inc

Johnson & Johnson

Kezar Life Sciences Inc

Neovacs SA

NovelMed Therapeutics Inc

Octapharma AG

Pfizer Inc

ReveraGen BioPharma Inc

Viela Bio Inc

Dermatomyositis - Drug Profiles

abatacept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baricitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BVX-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KZR-616 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lenabasum - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Dermatomyositis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06823859 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pirfenidone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium thiosulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tofacitinib citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tofacitinib citrate ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ustekinumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vamorolone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIB-7734 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dermatomyositis - Dormant Projects

Dermatomyositis - Discontinued Products

Dermatomyositis - Product Development Milestones

Featured News & Press Releases

Jun 12, 2019: Lenabasum open-label extension data to be presented at EULAR 2019 continue to show a favorable safety profile and improvement in efficacy outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies

Apr 01, 2019: Neovacs announces an agreement with Biosyn to diversify its supply of Keyhole Limpet Hemocyanin

Dec 18, 2018: Corbus Pharmaceuticals announces Issuance of Composition of Matter Patent related to Lenabasum

Dec 17, 2018: Corbus Pharmaceuticals initiates “DETERMINE” phase 3 study in Dermatomyositis

Sep 20, 2018: Corbus Pharmaceuticals provides update on Lenabasum

Jul 25, 2018: Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis

Jul 20, 2018: Corbus Pharmaceuticals receives FDA Orphan Drug Designation for Lenabasum for the treatment of Dermatomyositis

Jun 06, 2018: GNI Group Initiates Etuary Phase III Trial in China for CTD-ILD

Apr 26, 2018: Corbus Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference

Mar 02, 2018: Corbus Pharmaceuticals to Present at the Cowen & Co. 38th Annual Health Care Conference

Feb 06, 2018: Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference

Nov 27, 2017: Corbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic Diseases

Oct 31, 2017: Corbus Pharmaceuticals Announces New Patent Issuance Covering the Use of Anabasum for the Treatment of Inflammatory Diseases

Oct 19, 2017: Corbus Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis

Jul 19, 2017: Neovacs Announces FDA Acceptance of a New IND to Expand in U.S. IFN-alpha Kinoid Clinical Development Program in Dermatomyositis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Dermatomyositis - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis - Pipeline Review, H2 2019, provides an overview of the Dermatomyositis (Musculoskeletal Disorders) pipeline landscape.

Dermatomyositis is a rare inflammatory disease which is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dermatomyositis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dermatomyositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 4, 3, 2, 1 and 1 respectively.

Dermatomyositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomyositis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dermatomyositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dermatomyositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dermatomyositis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dermatomyositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.